| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Thalidomide-piperazine HCl targets the cereblon (CRBN) E3 ubiquitin ligase complex, similar to thalidomide and its analogs. By binding to cereblon, the compound modulates the ubiquitination and degradation of specific substrate proteins. It works by inhibiting the production of pro-inflammatory cytokines and modulating immune responses. Its ability to modulate angiogenesis and cell survival pathways also makes it a promising candidate for cancer treatment and other inflammatory conditions.
|
|---|---|
| ln Vitro |
In vitro, Thalidomide-piperazine HCl has been shown to modulate immune responses and inhibit pro-inflammatory cytokine production. The compound is used as a tool in developmental biology to study limb development pathways. Detailed in vitro activity data, including specific IC50 values and cell lines tested, are limited in the available literature.
|
| ln Vivo |
In vivo, Thalidomide-piperazine HCl has potential for the research of leprosy and multiple myeloma. The compound's ability to modulate angiogenesis and cell survival pathways makes it a promising candidate for cancer treatment and other inflammatory conditions. Detailed in vivo data regarding dosage, administration routes, and specific efficacy endpoints are limited.
|
| Enzyme Assay |
Thalidomide-piperazine HCl's receptor-binding activity involves binding to the cereblon (CRBN) E3 ubiquitin ligase complex. Binding assays typically involve measuring the interaction between the compound and cereblon using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). The compound's ability to modulate substrate ubiquitination and degradation can be assessed using cell-free ubiquitination assays.
|
| Cell Assay |
In vitro cell experiments with Thalidomide-piperazine HCl typically use cancer cell lines or developmental biology models. Cells are treated with the compound at various concentrations, and the effects on cell proliferation, cytokine production, angiogenesis, and limb development pathways are assessed. The compound's modulation of immune responses and cell survival is evaluated using standard biochemical and molecular biology assays.
|
| Animal Protocol |
In vivo animal studies with Thalidomide-piperazine HCl have been conducted using rodent models of multiple myeloma and leprosy. The compound is typically administered via oral gavage or intraperitoneal injection. Detailed protocols regarding dosage, treatment duration, and specific animal models are not extensively reported in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data specific to Thalidomide-piperazine HCl are limited in the available literature. As a small molecule with a molecular weight of 378.81, the compound is expected to have reasonable oral bioavailability. Further pharmacokinetic studies are needed to fully characterize its absorption, distribution, metabolism, and excretion properties.
|
| Toxicity/Toxicokinetics |
Thalidomide-piperazine HCl is considered safe for research use at typical concentrations. As a research compound, it is intended for laboratory use only and not for human consumption. The compound should be handled under standard laboratory safety practices with appropriate precautions due to the known teratogenic effects of thalidomide analogs.
|
| Additional Infomation |
Thalidomide-piperazine hydrochloride has a molecular formula of C17H19ClN4O4 and a molecular weight of 378.81. Standard purity is 98%. The compound is an E3 ligase building block and is used as a tool in developmental biology for studying limb development pathways. It has potential applications in the research of leprosy and multiple myeloma.
|
| Molecular Formula |
C17H19CLN4O4
|
|---|---|
| Molecular Weight |
378.81
|
| Exact Mass |
378.109
|
| CAS # |
2228029-82-9
|
| PubChem CID |
134562528
|
| Appearance |
Light yellow to green yellow solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
616
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
GZNLORFTQXVXFE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18N4O4.ClH/c22-14-4-3-13(15(23)19-14)21-16(24)11-2-1-10(9-12(11)17(21)25)20-7-5-18-6-8-20;/h1-2,9,13,18H,3-8H2,(H,19,22,23);1H
|
| Chemical Name |
2-(2,6-dioxopiperidin-3-yl)-5-piperazin-1-ylisoindole-1,3-dione;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~33.33 mg/mL (~87.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6398 mL | 13.1992 mL | 26.3985 mL | |
| 5 mM | 0.5280 mL | 2.6398 mL | 5.2797 mL | |
| 10 mM | 0.2640 mL | 1.3199 mL | 2.6398 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
